VaccinesMicrobiologyPeer-reviewed journal article
Long-term Immunity of a Microneedle Array Patch of SARS-CoV-2 S1 Protein Subunit Vaccine Irradiated by Gamma Rays in Mice
Eun KimiD, Muhammad S. KhaniD, Juyeop ShiniD, Shaohua HuangiD, Alessandro FerrariiD, Donghoon HaniD, Eun-Jin An, Thomas W. Kenniston, Irene CassanitiiD, Fausto BaldantiiD, Dohyeon JeongiD, Andrea A. GambottoiD
Abstract
COVID-19 vaccines effectively prevent symptomatic infection and severe disease, including hospitalization and death. However, unequal vaccine distribution during the pandemic, especially in low- and middle-income countries, has led to the emergence of vaccine-resistant strains. This underscores the need for alternative, safe, and thermostable vaccine platforms, such as dissolved microneedle array patches (MAP) delivering a subunit vaccine, which eliminate the need for cold chain and trained healthcare personnel. This study demonstrates that the SARS-CoV-2 S1 monomer with RS09, a TLR-4 agonist peptide, serves as an optimal protein subunit immunogen. This combination stimulates a stronger S1-specific immune response, resulting in binding to the membrane-bound spike on the cell surface and ACE2-binding inhibition, compared to the monomer S1 alone or trimer S1, regardless of RS09. MAP delivery of the rS1RS09 subunit vaccine elicited higher and longer-lasting immunity compared to conventional intramuscular injection. S1-specific IgG levels remained significantly elevated for up to 70 weeks post-administration. Additionally, different doses of 5, 15, and 45 g of MAP vaccines induced robust and sustained Th2-prevalent immune responses, suggesting a dose-sparing effect and inducing significantly high neutralizing antibodies against the Wuhan, Delta, and Omicron variants at 15 and 45 g dose. Moreover, gamma irradiation as a terminal sterilization method did not significantly affect immunogenicity, with irradiated vaccines maintaining comparable efficacy to non-irradiated ones. The stability of MAP vaccines was evaluated after long-term storage at room temperature and refrigeration for 19 months, showing minimal protein degradation. Further, after an additional one-month of storage at elevated temperature (42{degrees}C), rS1RS09 in both non-irradiated and irradiated MAP degraded less than 3%, while the liquid subunit vaccine degraded over 23%. Overall, these results indicate that gamma irradiation sterilized MAP-rS1RS09 vaccines maintain stability during extended storage without refrigeration, supporting their potential for mass production and widespread use in global vaccination efforts.
- organism: mouse
- assay: protein sequence
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- research focus: benchmarking
- approach: experimental assay
- Citations
- 4
- FWCI
- 2.67
- Field percentile
- top 12%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Fourth dose of Microneedle Array Patch of SARS-CoV-2 S1 Protein Subunit Vaccine Elicits Robust Long-lasting Humoral Responses in mice
E. Kim, J. Shin, … A. Gambotto·bioRxiv·Oct 5, 2023
- Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1
A. To, T. A. S. Wong, … A. T. Lehrer·ACS Infectious DiseasesPeer-reviewed·Mar 9, 2022
- Complete protection by a single dose skin patch delivered SARS-CoV-2 spike vaccine
C. L. D. McMillan, J. J. Y. Choo, … D. A. Muller·bioRxiv·May 30, 2021
- Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment
S. K. Malladi, R. Singh, … R. Varadarajan·bioRxiv·Aug 15, 2020
- Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine
P. S. Arunachalam, Y. Feng, … B. Pulendran·bioRxiv·Mar 18, 2022
- Enhanced immunogenicity of a synthetic DNA vaccine expressing consensus SARS-CoV-2 Spike protein using needle-free immunization
S. S. Alamri, K. A. Alluhaybi, … A. M. Hashem·bioRxiv·Feb 1, 2021